#weight-loss-drugs

#weight-loss-drugs

Figures from the British Association of Aesthetic Plastic Surgeons (Baaps) show facelifts are on the rise in the UK. In 2024 there were 1,882 procedures, up 8% from the previous year. Women accounted for the majority, with numbers rising by 7% to 1,742. But the steepest increase came from men: procedures grew by 26%, from 111 in 2023 to 140 in 2024.

"FDA policymakers have tried to come up with ideas to speed important products to market. ... It is in part directed to achieving some of the (Trump) Administration's goals," said Chad Landmon, chair of Polsenelli's patent and FDA practice.

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks. Their effect may not last after discontinuing use, and side effects including osteoporosis and muscle loss have raised concerns about long-term harms. They also induce nausea, which can make it difficult to stay the course of treatment.

It's difficult to envision a return to pre-pandemic levels of body positivity as brands continue to focus more on conventional beauty standards and thinness.

A study has been launched due to reports of serious side effects related to weight loss drugs potentially affecting the pancreas, prompting safety investigations.

In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition.

The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration.

Hims & Hers reported a remarkable 111% revenue increase to $586 million, driving its stock up 18%, alongside a 345% net income rise.